Editor’s Note November 29, 2011
OneMedForum SF 2012 is around the corner and we are gearing up to present some of the most promising companies and technologies, as well as […]
Month: November 2011
EpiCept’s Ceplene Product Receives Marketing Auth. by European Commission
Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.
S.E.A. Medical Improves IV Drug Delivery
S.E.A. Medical Systems, Inc. is developing solutions for making intravenous (IV) drug delivery safer for patients.
GlySure Develops a Continuous Glucose Monitoring System
GlySure has developed an intravascular sensor capable of continuously monitoring a patient’s glucose for the length of their stay in the ICU.
Editor’s Note November 22, 2011
OneMedForum SF 2012 is around the corner and we are gearing up to present some of the most promising companies and technologies, as well as […]
DATATRAK’s Product Suite Expands Into Chinese Market Through Tigermed Partnership
DATATRAK International, Inc. announced translation of DATATRAK ONE to Simplified Chinese
Dec 13-14, 2011 Oppenheimer Annual Healthcare Conference
The Oppenheimer 22nd Annual Healthcare Conference will take place at the Waldorf=Astoria in New York City, December 13-14, 2011. This conference will present a core […]
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Neovasc’s Refractory Angina Treatment Receives CE Mark
Results of a published prospective three-year clinical study have demonstrated that the Reducer is safe and effective at providing relief of angina symptoms in refractory angina patients.
Wound Management Activates Orthopedic Business; Partner Chosen to Develop Products Based on its Patent
Wound Management announced that its subsidiary, Resorbable Orthopedic Products has entered into an agreement with BioStructures.